Day One Biopharmaceuticals (DAWN)
(Delayed Data from NSDQ)
$14.23 USD
+0.82 (6.11%)
Updated Aug 15, 2024 04:00 PM ET
After-Market: $14.25 +0.02 (0.14%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Brokerage Reports
0 items in cart
Day One Biopharmaceuticals, Inc. [DAWN]
Reports for Purchase
Showing records 1 - 20 ( 79 total )
Company: Day One Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Day One Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
DAWN Enters Ex-US Licensing Agreement with Ipsen; Receives $111M as Upfront
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Day One Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
A Closer Look at Targeting Solid Tumors with a PTK7 ADC (DAY301)
Provider: H.C. Wainwright & Co., Inc.
Analyst: MALDONADO A
Company: Day One Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Enters ADC Space; Grabs Exclusive License for PTK7 ADC
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Day One Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Key Takeaways for ASCO 2024; Roundup for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Day One Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Day One Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Sale of PRV Nets ~$100M in Non-Dilutive Financing for Ojemda
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Day One Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology -ASCO 2024 Abstract Roundup for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: Research Department
Company: Day One Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Q1 Financials; First Ojemda Prescriptions Received
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Day One Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Day One Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Ojemda on the Brain?Thoughts on Launch Dynamics Post Approval; Reit. Buy and Lowering Our PT to $40
Provider: H.C. Wainwright & Co., Inc.
Analyst: MALDONADO A
Company: Day One Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
FIREFLY-1 Lights Pathway for Newly Approved Ojemda (tovorafenib) In r/pLGG
Provider: H.C. Wainwright & Co., Inc.
Analyst: MALDONADO A
Company: Day One Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
New RAF on the Block; OJEMDA Gets Accelerated Approval
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Day One Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Day One Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Day One Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Day One Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Day One Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
At the DAWN of Tovo?s PDUFA, a Look at Programs on the Horizon Furthers Our Overall Conviction
Provider: H.C. Wainwright & Co., Inc.
Analyst: MALDONADO A
Company: Day One Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Day One Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department